Search Results - "CROWN, John P"

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98 by LOI, Sherene, SIRTAINE, Nicolas, DE AZAMBUJA, Evandro, QUINAUX, Emmanuel, DI LEO, Angelo, MICHIELS, Stefan, PICCART, Martine J, SOTIRIOU, Christos, PIETTE, Fanny, SALGADO, Roberto, VIALE, Giuseppe, VAN EENOO, Françoise, ROUAS, Ghizlane, FRANCIS, Prudence, CROWN, John P. A, HITRE, Erika

“…Previous preclinical and clinical data suggest that the immune system influences prognosis and response to chemotherapy (CT); however, clinical relevance has…”
Get full text

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study by Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof

“…Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs) 4 and 6 with preclinical evidence of…”
Get full text

Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer by CROWN, John P, DIERAS, Véronique, GREIL, Richard, COGNETTI, Francesco, FOUNTZILAS, George, BLASINSKA-MORAWIEC, Maria, LIEDTKE, Cornelia, KREIENBERG, Rolf, MILLER, Wilson H, TASSELL, Vanessa, XIN HUANG, PAOLINI, Jolanda, STAROSLAWSKA, Elzbieta, KERN, Kenneth A, ROMIEU, Gilles, YARDLEY, Denise A, BACHELOT, Thomas, DAVIDSON, Neville, WILDIERS, Hans, FASCHING, Peter A, CAPITAIN, Olivier, RAMOS, Manuel

“…Metastatic breast cancer (MBC) remains an incurable illness in the majority of cases, despite major therapeutic advances. This may be related to the ability of…”
Get full text

effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial by de Azambuja, Evandro, McCaskill-Stevens, Worta, Francis, Prudence, Quinaux, Emmanuel, Crown, John P. A, Vicente, Malou, Giuliani, Rosa, Nordenskjöld, Bo, Gutiérez, Jorge, Andersson, Michael, Vila, Mireia Margeli, Jakesz, Raimund, Demol, Jan, Dewar, Joanna, Santoro, Armando, Lluch, Ana, Olsen, Steven, Gelber, Richard D, Di Leo, Angelo, Piccart-Gebhart, Martine

“…Background: Obesity has been shown to be an indicator of poor prognosis for patients with primary breast cancer (BC) regardless of the use of adjuvant systemic…”
Get full text

A careful reassessment of anthracycline use in curable breast cancer by Hurvitz, Sara Alsterlind, McAndrew, Nicholas P., Bardia, Aditya, Press, Michael F., Pegram, Mark, Crown, John P., Fasching, Peter A., Ejlertsen, Bent, Yang, Eric H., Glaspy, John A., Slamon, Dennis J.

“…It has been over three decades since anthracyclines took their place as the standard chemotherapy backbone for breast cancer in the curative setting. Though…”
Get full text

High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials by BERRY, Donald A, UENO, Naoto T, CROWN, John P, SCHMID, Peter, LOTZ, Jean-Pierre, ROSTI, Giovanni, BREGNI, Marco, DEMIRER, Taner, JOHNSON, Marcella M, XIUDONG LEI, CAPUTO, Jean, SMITH, Dori A, YANCEY, Linda J, CRUMP, Michael, STADTMAUER, Edward A, BIRON, Pierre

“…High doses of effective chemotherapy are compelling if they can be delivered safely. Substantial interest in supporting high-dose chemotherapy with bone marrow…”
Get full text

Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland by McSorley, Lynda M, Tharmabala, Mehala, Al Rahbi, Fathiya, Keane, Fergus, Evoy, Denis, Geraghty, James G, Rothwell, Jane, McCartan, Damian P, Greally, Megan, O'Connor, Miriam, O'Mahony, Deirdre, Keane, Maccon, Kennedy, Michael John, O'Reilly, Seamus, Millen, Steve J, Crown, John P, Kelly, Catherine M, Prichard, Ruth S, Quinn, Cecily M, Walshe, Janice M

“…This study, using real-world data, assesses the impact of RS testing on treatment pathways and the associated economic consequences of such testing. This paper…”
Get full text

Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial by Earl, Helena M, Professor, Hiller, Louise, PhD, Howard, Helen C, PhD, Dunn, Janet A, Prof, Young, Jennie, BA, Bowden, Sarah J, PhD, McDermaid, Michelle, Waterhouse, Anna K, BSc, Wilson, Gregory, FRCP, Agrawal, Rajiv, FRCR, O'Reilly, Susan, MD, Bowman, Angela, MB ChB, Ritchie, Diana M, MD, Goodman, Andrew, MB ChB, Hickish, Tamas, Prof, McAdam, Karen, FRCP, Cameron, David, Prof, Dodwell, David, Prof, Rea, Daniel W, FRCP, Caldas, Carlos, Prof, Provenzano, Elena, PhD, Abraham, Jean E, PhD, Canney, Peter, MD, Crown, John P, Prof, Kennedy, M John, Prof, Coleman, Robert, Prof, Leonard, Robert C, Prof, Carmichael, James A, MD, Wardley, Andrew M, Prof, Poole, Christopher J, Prof

“…Summary Background The tAnGo trial was designed to investigate the potential role of gemcitabine when added to anthracycline and taxane-containing adjuvant…”
Get full text

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab by Ganz, Patricia A., Cecchini, Reena S., Fehrenbacher, Louis, Geyer, Charles E., Rastogi, Priya, Crown, John P., Thirlwell, Michael P., Ellison, David M., Boileau, Jean-Francois, Flynn, Patrick J., Jeong, Jong-Hyeon, Mamounas, Eleftherios P., Wolmark, Norman

“…The NRG Oncology/NSABP B-47 menstrual history (MH) study examined trastuzumab effects on menstrual status and associated circulating reproductive hormones. MH…”
Get full text

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2 by Fehrenbacher, Louis, Cecchini, Reena S, Geyer, Jr, Charles E, Rastogi, Priya, Costantino, Joseph P, Atkins, James N, Crown, John P, Polikoff, Jonathan, Boileau, Jean-Francois, Provencher, Louise, Stokoe, Christopher, Moore, Timothy D, Robidoux, André, Flynn, Patrick J, Borges, Virginia F, Albain, Kathy S, Swain, Sandra M, Paik, Soonmyung, Mamounas, Eleftherios P, Wolmark, Norman

“…Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of…”
Get full text

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 by Finn, Richard S, Crown, John P, Ettl, Johannes, Schmidt, Marcus, Bondarenko, Igor M, Lang, Istvan, Pinter, Tamas, Boer, Katalin, Patel, Ravindranath, Randolph, Sophia, Kim, Sindy T, Huang, Xin, Schnell, Patrick, Nadanaciva, Sashi, Bartlett, Cynthia Huang, Slamon, Dennis J

“…Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6. In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial,…”
Get full text

miR-187 Is an Independent Prognostic Factor in Breast Cancer and Confers Increased Invasive Potential In Vitro by MULRANE, Laoighse, MADDEN, Stephen F, GALLAGHER, William M, O'CONNOR, Darran P, BRENNAN, Donal J, GREMEL, Gabriela, MCGEE, Sharon F, MCNALLY, Sara, MARTIN, Finian, CROWN, John P, JIRSTRÖM, Karin, HIGGINS, Desmond G

“…Here, we describe an integrated bioinformatics, functional analysis, and translational pathology approach to identify novel miRNAs involved in breast cancer…”
Get full text

BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer by Walsh, Louise, Haley, Kathryn E, Moran, Bruce, Mooney, Brian, Tarrant, Finbarr, Madden, Stephen F, Di Grande, Alessandra, Fan, Yue, Das, Sudipto, Rueda, Oscar M, Dowling, Catríona M, Varešlija, Damir, Chin, Suet-Feung, Linn, Sabine, Young, Leonie S, Jirström, Karin, Crown, John P, Bernards, Rene, Caldas, Carlos, Gallagher, William M, O'Connor, Darran P, Ní Chonghaile, Tríona

“…Invasive lobular carcinoma (ILC) is a subtype of breast cancer accounting for 10% of breast tumors. The majority of patients are treated with endocrine…”
Get full text

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer by O'Leary, Patrick C, Terrile, Marta, Bajor, Malgorzata, Gaj, Pawel, Hennessy, Bryan T, Mills, Gordon B, Zagozdzon, Agnieszka, O'Connor, Darran P, Brennan, Donal J, Connor, Kate, Li, Jane, Gonzalez-Angulo, Ana Maria, Sun, Han-Dong, Pu, Jian-Xin, Pontén, Fredrik, Uhlén, Mathias, Jirström, Karin, Nowis, Dominika A, Crown, John P, Zagozdzon, Radoslaw, Gallagher, William M

“…Peroxiredoxin-1 (PRDX1) is a multifunctional protein, acting as a hydrogen peroxide (H2O2) scavenger, molecular chaperone and immune modulator. Although…”
Get full text

High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials by BERRY, Donald A, UENO, Naoto T, BERGH, Jonas, NITZ, Ulrike A, GIANNI, Alessandro M, BASSER, Russell L, ZANDER, Axel R, COOMBES, R. Charles, ROCHE, Henri, TOKUDA, Yutaka, DE VRIES, Elisabeth G. E, HORTOBAGYI, Gabriel N, JOHNSON, Marcella M, CROWN, John P, PEDRAZZOLI, Paolo, BREGNI, Marco, DEMIRER, Taner, XIUDONG LEI, CAPUTO, Jean, RODENHUIS, Sjoerd, PETERS, William P, LEONARD, Robert C, BARLOW, William E, TALLMAN, Martin S

“…Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to…”
Get full text

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib by Crown, John P., Burris, Harold A., Boyle, Fran, Jones, Suzanne, Koehler, Maria, Newstat, Beth O., Parikh, Roma, Oliva, Cristina, Preston, Alaknanda, Byrne, Julie, Chan, Steve

“…Purpose To characterize diarrhea events in patients with cancer treated with lapatinib as monotherapy or in combination with capecitabine or taxanes. Patients…”
Get full text

p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial by Sonnenblick, Amir, Salgado, Roberto, Brohée, Sylvain, Zahavi, Tamar, Peretz, Tamar, Van den Eynden, Gert, Rouas, Ghizlane, Salmon, Asher, Francis, Prudence A, Di Leo, Angelo, Crown, John P A, Viale, Giuseppe, Daly, Laura, Javdan, Bahar, Fujisawa, Sho, De Azambuja, Evandro, Lieveke, Ameye, Piccart, Martine J, Bromberg, Jacqueline F, Sotiriou, Christos

“…In the present study, in order to investigate the role of signal transducer and activator of transcription 3 (STAT3) in estrogen receptor (ER)-positive breast…”
Get full text

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients by van den Hurk, Karin, Balint, Balazs, Toomey, Sinead, O'Leary, Patrick C, Unwin, Louise, Sheahan, Kieran, McDermott, Enda W, Murphy, Ian, van den Oord, Joost J, Rafferty, Mairin, FitzGerald, Dara M, Moran, Julie, Cummins, Robert, MacEneaney, Owen, Kay, Elaine W, O'Brien, Cathal P, Finn, Stephen P, Heffron, Cynthia C B B, Murphy, Michelle, Yela, Ruben, Power, Derek G, Regan, Padraic J, McDermott, Clodagh M, O'Keeffe, Allan, Orosz, Zsolt, Donnellan, Paul P, Crown, John P, Hennessy, Bryan T, Gallagher, William M

“…Because of advances in targeted therapies, the clinical evaluation of cutaneous melanoma is increasingly based on a combination of traditional histopathology…”
Get full text

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib by Crown, John P., Burris, Harold A., Boyle, Fran, Jones, Suzanne, Koehler, Maria, Newstat, Beth O., Parikh, Roma, Oliva, Cristina, Preston, Alaknanda, Byrne, Julie, Chan, Steve

Get full text

Medical problems in patients with malignancy: case 3. Ulcerating cytomegalovirus bronchitis in a patient with relapsed non-Hodgkin's lymphoma by Ooi, Wei S, Crown, John P

Get full text